MELT-300's NDA submission will test whether Harrow can convert a compounded sedation product into an FDA-approved asset atop a maturing ophthalmic commercial platform

Bull

A complete and accepted NDA submission would validate the clinical and pharmacokinetic data package assembled across all ancillary studies, signaling that the FDA views MELT-300's sublingual medetomidine-ketamine-ondansetron formulation as approvable and that Harrow has successfully navigated the 505(b)(2) or full NDA pathway; this would de-risk the commercial launch timeline, support a premium pricing strategy over the compounded MKO Melt predecessor, and expand the addressable market by enabling hospital and ASC formulary access that is difficult to achieve with a compounded product.

Bear

The most likely failure modes are deficiencies in the non-clinical animal study or one or more of the three pharmacokinetic studies that delay or prevent NDA filing, or an FDA Complete Response Letter citing inadequate safety data for the sedation indication given the narrow therapeutic index of the ketamine component; regulatory risk is amplified because procedural sedation carries significant patient safety stakes, and any signal of respiratory or cardiovascular adverse events could prompt the FDA to require additional clinical data, pushing the program well beyond the planned submission window.